Global Research and Evidence Lab 14 August 2024 First Read lpsen SA lqirvo key competitor drug approved lqirvo key competitor drug seladelpar from Gilead received FDA approval A key investor focus on Ipsen is the Igirvo launch in H2. This is a drug that was recently approved in a rare liver disease, 2L PBC, and is in a tight competition with Gilead's Livdelzi (seladelpar). Livdelzi received FDA approval this evening, the timing was as expected. We note the following when comparing Livdelzi (label here) and ...